ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Interpretable CRAM‑Enhanced Lightweight Dual‑Branch CNN for Real‑Time Breast Cancer Histopathology in Internet‑of‑Medical‑Things Environments.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a primary global health concern, with histopathological image analysis serving as the diagnostic gold standard. However, manual microscopy is time-consuming and often subjective. While deep learning offers a powerful solution, existing models are typically too complex and opaque for real-time use in Internet of Medical Things (IoMT) environments. To address this, we propose an interpretable and lightweight hybrid deep learning model that combines MobileNetV2 and EfficientNet-B0, enhanced by a novel contextual recurrent attention module (CRAM). CRAM refines fused features through attention-based weighting, improving focus on diagnostically relevant regions. The model achieved 99.9% classification accuracy and an AUC of 1.00, outperforming standalone baselines while remaining efficient (∼12 M parameters) and suitable for IoMT deployment. Interpretability is ensured through integrated Grad-CAM and SHAP analyses, which visually and quantitatively explain predictions by highlighting malignant tissue features that align with pathologist judgment. This balance of accuracy, efficiency, and transparency enables real-time, trustworthy diagnostics for resource-limited and point-of-care settings. Future work includes extending to multi-class tumor subtypes and clinical validation in real-world workflows. The proposed system represents a significant step toward making AI in digital pathology more accessible and explainable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.